Arrivent Biopharma Inc (AVBP)

$20.82 -0.35 (-1.65%)
Market Cap 720.12M
Revenue (ttm) 0.00
Net Income (ttm) -80.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 158,300
Avg Vol 215,792
Day's Range N/A - N/A
Shares Out 34.02M
Stochastic %K 81%
Beta 1.66
Analysts Strong Sell
Price Target $39.28

Latest News on AVBP

ArriVent BioPharma Reports Full Year 2024 Financial Results

Mar 3, 2025, 7:00 AM EST - 7 weeks ago

ArriVent BioPharma Reports Full Year 2024 Financial Results

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Jan 21, 2025, 7:00 PM EST - 3 months ago

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Sep 9, 2024, 12:05 PM EDT - 8 months ago

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

Aug 15, 2024, 7:01 AM EDT - 9 months ago

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:01 PM EDT - 9 months ago

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

Aug 12, 2024, 8:00 AM EDT - 9 months ago

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

Jun 5, 2024, 7:00 AM EDT - 11 months ago

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 16, 2024, 4:05 PM EDT - 1 year ago

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

ArriVent BioPharma Reports First Quarter 2024 Financial Results

May 8, 2024, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports First Quarter 2024 Financial Results

ArriVent Appoints Kristine Peterson to its Board of Directors

Apr 22, 2024, 4:05 PM EDT - 1 year ago

ArriVent Appoints Kristine Peterson to its Board of Directors

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Mar 28, 2024, 8:30 PM EDT - 1 year ago

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

ArriVent BioPharma Reports Full Year 2023 Financial Results

Mar 28, 2024, 4:05 PM EDT - 1 year ago

ArriVent BioPharma Reports Full Year 2023 Financial Results

ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment

Jan 29, 2024, 6:15 PM EST - 1 year ago

ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment